WO2004058797A3 - Human monoclonal antibodies against interleukin 8 (il-8) - Google Patents

Human monoclonal antibodies against interleukin 8 (il-8) Download PDF

Info

Publication number
WO2004058797A3
WO2004058797A3 PCT/US2003/040039 US0340039W WO2004058797A3 WO 2004058797 A3 WO2004058797 A3 WO 2004058797A3 US 0340039 W US0340039 W US 0340039W WO 2004058797 A3 WO2004058797 A3 WO 2004058797A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
monoclonal antibodies
antibodies
human monoclonal
antibodies against
Prior art date
Application number
PCT/US2003/040039
Other languages
French (fr)
Other versions
WO2004058797A2 (en
Inventor
Jessica Teeling
Paul Parren
Ole D M Sc Baadsgaard
Debra Hudson
Joergen Petersen
Original Assignee
Medarex Inc
Genmab As
Jessica Teeling
Paul Parren
Ole D M Sc Baadsgaard
Debra Hudson
Joergen Petersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32681965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004058797(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2510087A priority Critical patent/CA2510087C/en
Priority to AT03799925T priority patent/ATE527278T1/en
Priority to JP2004563614A priority patent/JP4739763B2/en
Priority to ES03799925T priority patent/ES2373947T3/en
Priority to AU2003299641A priority patent/AU2003299641C1/en
Application filed by Medarex Inc, Genmab As, Jessica Teeling, Paul Parren, Ole D M Sc Baadsgaard, Debra Hudson, Joergen Petersen filed Critical Medarex Inc
Priority to NZ541050A priority patent/NZ541050A/en
Priority to EP03799925A priority patent/EP1590364B1/en
Publication of WO2004058797A2 publication Critical patent/WO2004058797A2/en
Priority to NO20053417A priority patent/NO338054B1/en
Priority to HK06104337.8A priority patent/HK1082749A1/en
Publication of WO2004058797A3 publication Critical patent/WO2004058797A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
PCT/US2003/040039 2002-12-16 2003-12-16 Human monoclonal antibodies against interleukin 8 (il-8) WO2004058797A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP03799925A EP1590364B1 (en) 2002-12-16 2003-12-16 Human monoclonal antibodies against interleukin 8 (il-8)
AT03799925T ATE527278T1 (en) 2002-12-16 2003-12-16 HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
JP2004563614A JP4739763B2 (en) 2002-12-16 2003-12-16 Human monoclonal antibody against interleukin 8 (IL-8)
ES03799925T ES2373947T3 (en) 2002-12-16 2003-12-16 HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUCINE 8 (IL-8).
AU2003299641A AU2003299641C1 (en) 2002-12-16 2003-12-16 Human monoclonal antibodies against interleukin 8 (IL-8)
CA2510087A CA2510087C (en) 2002-12-16 2003-12-16 Human monoclonal antibodies against interleukin 8 (il-8)
NZ541050A NZ541050A (en) 2002-12-16 2003-12-16 Human monoclonal antibodies against interleukin 8 (IL-8)
NO20053417A NO338054B1 (en) 2002-12-16 2005-07-14 Human monoclonal antibody to IL-8, method for producing the antibody, pharmaceutical composition comprising the antibody, and use thereof.
HK06104337.8A HK1082749A1 (en) 2002-12-16 2006-04-10 Human monoclonal antibodies against interleukin 8 (il-8)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43372802P 2002-12-16 2002-12-16
US60/433,728 2002-12-16

Publications (2)

Publication Number Publication Date
WO2004058797A2 WO2004058797A2 (en) 2004-07-15
WO2004058797A3 true WO2004058797A3 (en) 2007-01-25

Family

ID=32681965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040039 WO2004058797A2 (en) 2002-12-16 2003-12-16 Human monoclonal antibodies against interleukin 8 (il-8)

Country Status (11)

Country Link
US (9) US7282568B2 (en)
EP (1) EP1590364B1 (en)
JP (1) JP4739763B2 (en)
AT (1) ATE527278T1 (en)
AU (1) AU2003299641C1 (en)
CA (1) CA2510087C (en)
ES (1) ES2373947T3 (en)
HK (1) HK1082749A1 (en)
NO (1) NO338054B1 (en)
NZ (1) NZ541050A (en)
WO (1) WO2004058797A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945580B2 (en) 2007-07-11 2015-02-03 Ibio Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US9115201B2 (en) 2008-09-28 2015-08-25 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP4739763B2 (en) * 2002-12-16 2011-08-03 ゲンマブ エー／エス Human monoclonal antibody against interleukin 8 (IL-8)
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2005058234A2 (en) * 2003-12-11 2005-06-30 Yale University Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation
PE20060560A1 (en) 2004-08-03 2006-06-27 Novartis Ag HUMAN INTERLEUKIN-4 ANTIBODIES
JP2008523083A (en) * 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer
WO2006074430A2 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
WO2006113643A2 (en) * 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
EP4342995A2 (en) 2006-03-31 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2008062310A2 (en) * 2006-05-19 2008-05-29 Hornedo Jose Luis Stephano Elimination of the bacteria that cause pierce's disease
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
EP2046383B1 (en) 2006-07-04 2014-11-19 Genmab A/S Cd20 binding molecules for the treatment of copd
LT2081595T (en) 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP2068928A2 (en) * 2006-09-28 2009-06-17 Merck Serono SA Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
GB0704651D0 (en) * 2007-03-09 2007-04-18 Ucl Business Plc Composition
CL2008001071A1 (en) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases.
WO2008141275A1 (en) * 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
UA107557C2 (en) * 2007-07-06 2015-01-26 OFATUMUMAB ANTIBODY COMPOSITION
WO2009016839A1 (en) 2007-08-01 2009-02-05 Japan Science And Technology Agency Method for measurement of concentration of antigen
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
KR102269708B1 (en) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
WO2010105243A1 (en) 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
ES2812537T3 (en) 2009-10-21 2021-03-17 Agios Pharmaceuticals Inc Methods and compositions for disorders related to cell proliferation
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3613774A1 (en) 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
RS56599B1 (en) 2010-06-15 2018-02-28 Genmab As Human antibody drug conjugates against tissue factor
FR2961695B1 (en) * 2010-06-29 2012-07-06 Galderma Res & Dev USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS
KR101247641B1 (en) 2010-10-22 2013-03-29 성균관대학교산학협력단 Composition of treatment for infectious and inflammatory diseases comprising peptide ligand binding to CXCR2
TWI619811B (en) 2010-11-08 2018-04-01 諾華公司 Chemokine receptor binding polypeptides
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
HUE039269T2 (en) 2011-05-03 2018-12-28 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
UA117451C2 (en) 2012-01-06 2018-08-10 Аджиос Фармасьютікалз, Інк. Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
TWI717591B (en) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 Fcγ riib-specific fc region variant
MX365747B (en) 2012-10-15 2019-06-12 Agios Pharmaceuticals Inc Therapeutic compounds and compositions.
KR20200134340A (en) 2013-01-10 2020-12-01 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
KR20210037745A (en) * 2013-03-15 2021-04-06 제넨테크, 인크. Cell culture compositions with antioxidants and methods for polypeptide production
KR20210130260A (en) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc region variant
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102302091B1 (en) 2013-07-11 2021-09-16 아지오스 파마슈티컬스 아이엔씨. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20220070066A (en) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. Pharmaceutical compositions of therapeutically active compounds
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
AU2015283812A1 (en) * 2014-07-02 2017-02-09 Bionomics Limited Predictive baseline biomarkers for use of vascular disrupting agents
WO2016019062A1 (en) * 2014-07-29 2016-02-04 Alliance Of Cardiovascular Researchers Priming of pancreatic tumors cells and cancer stem cells to trail-induced apoptosis
MA41294A (en) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE
CN114773470A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
SI3307271T1 (en) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
US10940126B2 (en) 2015-07-03 2021-03-09 Camilla Svensson Inhibition of IL-8 in the treatment of pain and/or bone loss
EP4140486A1 (en) 2015-07-03 2023-03-01 Lars Klareskog Methods and compounds for the alleviation and/or prevention of pain
BR122024000250A2 (en) 2015-10-15 2024-02-27 Les Laboratoires Servier USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT
UA123401C2 (en) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Combination therapy for treating malignancies
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
FI20165814A (en) 2016-10-27 2018-04-28 Tilt Biotherapeutics Oy INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20200131576A1 (en) * 2017-04-25 2020-04-30 The Brigham And Women's Hospital, Inc. IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
EP3679364A1 (en) 2017-09-07 2020-07-15 Bristol-Myers Squibb Company Method of purity determination by capillary electrophoresis
CA3080429A1 (en) * 2017-11-01 2019-05-09 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
US11572405B2 (en) 2018-01-12 2023-02-07 Bristol-Myers Squibb Company Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
MX2020009296A (en) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use.
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021048852A1 (en) 2019-09-11 2021-03-18 Yeda Research And Development Co. Ltd. Methods of treating breast cancer
JP2023505150A (en) 2019-12-02 2023-02-08 セルジーン コーポレーション Therapies for the treatment of cancer
CN115666704A (en) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 Ingestible device for delivery of therapeutic agents to the gastrointestinal tract
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2022031882A1 (en) * 2020-08-06 2022-02-10 Stelexis Therapeutics, Llc Il-8 antibodies and methods of use thereof
TW202227081A (en) * 2020-09-15 2022-07-16 美商雅力思提雅治療公司 Compositions and methods for the treatment of palmoplantar pustulosis
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
CN115414354A (en) * 2022-08-29 2022-12-02 西南医科大学 Application of xanthotoxin in preparation of medicine for treating thrombocytopenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US6984720B1 (en) * 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5652338A (en) * 1988-03-16 1997-07-29 The United States Of America As Represented By The Department Of Health And Human Services Neutrophil chemotactic factor
KR900700615A (en) * 1988-05-02 1990-08-16 고우지 마쯔시마 Method for preparing human neutrophil chemotactic factor polypeptide
EP0431042B1 (en) * 1988-08-29 1994-10-26 The Government of the United States Of America, as represented by The Secretary, Department of Health and Human Services A method of preparing an active human neutrophil chemotactic factor polypeptide
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US5776457A (en) * 1991-03-29 1998-07-07 Genentech, Inc. Antibodies to human PF4A receptor and compositions thereof
JP4156662B2 (en) 1991-03-29 2008-09-24 ジェネンテック・インコーポレーテッド Human PF4A receptor and use thereof
US5840856A (en) * 1991-03-29 1998-11-24 Genentech, Inc. Antibodies to a human PF4 superfamily receptor
US5919896A (en) * 1991-03-29 1999-07-06 Genentech, Inc. PF4A receptor
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5783415A (en) * 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US6087475A (en) * 1991-12-19 2000-07-11 Genentech, Inc. PF4A receptor
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
US6200558B1 (en) * 1993-09-14 2001-03-13 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
JP2575140Y2 (en) * 1993-12-15 1998-06-25 株式会社小糸製作所 Vehicle lighting
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
BR9507545A (en) * 1994-04-28 1997-08-05 Music Vending Inc Music selling system
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
WO1996022785A1 (en) 1995-01-23 1996-08-01 The Regents Of The University Of California Methods for the treatment of acid aspiration-induced acute lung injury
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US20010006637A1 (en) * 1996-04-19 2001-07-05 Tohru Akahoshi Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
US6497878B1 (en) 1996-04-23 2002-12-24 Chugai Seiyaku Kabushiki Kaisha Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
EP0955060A1 (en) 1996-06-26 1999-11-10 Chugai Seiyaku Kabushiki Kaisha Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient
CA2268085A1 (en) * 1996-10-22 1998-04-30 Go Wakabayashi Sepsis remedy comprising anti-il-8 antibody as active ingredient
US6075475A (en) * 1996-11-15 2000-06-13 Ellis; Randy E. Method for improved reproduction of digital signals
CN1068524C (en) 1997-06-23 2001-07-18 叶庆炜 Process for preparing medicine for curing intractable psoriasis
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6423321B2 (en) * 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
IL129180A0 (en) 1999-03-25 2000-02-17 Technion Res & Dev Foundation Method and pharmaceutical composition for wound healing
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
DE19952622A1 (en) 1999-11-02 2001-05-10 Bayer Ag Process for the production of recombinant interleukin-8 and interleukin-8 muteins
US6420346B1 (en) 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
AR030753A1 (en) 2000-09-25 2003-09-03 Smithkline Beecham Corp USE OF MODULATORS-PROTEIN OF IL-8, GROALFA, GROBETA, GROGAMMA, NAP-2, AND ENA-78, TO TREAT VIRIC INFECTIONS
JP4739763B2 (en) 2002-12-16 2011-08-03 ゲンマブ エー／エス Human monoclonal antibody against interleukin 8 (IL-8)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US6984720B1 (en) * 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US8945580B2 (en) 2007-07-11 2015-02-03 Ibio Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US9115201B2 (en) 2008-09-28 2015-08-25 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof

Also Published As

Publication number Publication date
US20100303823A1 (en) 2010-12-02
US20080118517A1 (en) 2008-05-22
JP2006523088A (en) 2006-10-12
US10066012B2 (en) 2018-09-04
ATE527278T1 (en) 2011-10-15
EP1590364B1 (en) 2011-10-05
US11339215B2 (en) 2022-05-24
EP1590364A4 (en) 2008-11-19
US10253093B2 (en) 2019-04-09
ES2373947T3 (en) 2012-02-10
US20140170156A1 (en) 2014-06-19
US7622559B2 (en) 2009-11-24
NO338054B1 (en) 2016-07-25
US20170334984A9 (en) 2017-11-23
JP4739763B2 (en) 2011-08-03
CA2510087C (en) 2018-09-04
NO20053417L (en) 2005-07-14
US20230042255A1 (en) 2023-02-09
US20120164143A1 (en) 2012-06-28
US20170190770A2 (en) 2017-07-06
EP1590364A2 (en) 2005-11-02
NZ541050A (en) 2010-06-25
US20160280780A1 (en) 2016-09-29
AU2003299641A1 (en) 2004-07-22
AU2003299641A8 (en) 2004-07-22
AU2003299641C1 (en) 2016-06-02
AU2003299641B2 (en) 2011-06-02
US20180134783A9 (en) 2018-05-17
US8105588B2 (en) 2012-01-31
US20040208873A1 (en) 2004-10-21
US20190248883A1 (en) 2019-08-15
US8603469B2 (en) 2013-12-10
HK1082749A1 (en) 2006-06-16
US20180251540A1 (en) 2018-09-06
CA2510087A1 (en) 2004-07-15
US7282568B2 (en) 2007-10-16
WO2004058797A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
WO2004058797A3 (en) Human monoclonal antibodies against interleukin 8 (il-8)
LTC3284753I2 (en)
WO2004045512A3 (en) Human monoclonal antibodies against cd25
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2003017935A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2003059282A3 (en) Human monoclonal antibodies against cd30
WO2004056847A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2005023177A3 (en) Human monoclonal antibodies against bacillusanthracis protective antigen
WO2001009187A3 (en) Human monoclonal antibodies to her2/neu
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
CA2380783A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2510087

Country of ref document: CA

Ref document number: 2004563614

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003299641

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 541050

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1561/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003799925

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003799925

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)